ClinicalTrials.Veeva

Menu

Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)

C

Carmen Hidalgo Tenorio

Status and phase

Completed
Phase 4

Conditions

HIV Infections

Treatments

Drug: BIC/FTC/TAF

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT06177574
BIC-NOW

Details and patient eligibility

About

The goal of this study is to analyze in treatment-naïve HIV patients the antiviral activity, using a test and treat strategy, in real life of BIC/FTC/TAF. Secondary, this study aims to evaluate outcomes for implementation of the evidence based test and treat strategy.

Enrollment

208 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. HIV-1 infected adults (>17 y.o.)
  2. Antiretroviral-naïve.
  3. Be able to comply with protocol requirements and instructions.
  4. Subject or the subject's representative capable of giving signed informed consent

Exclusion criteria

  1. Women who are breastfeeding or plan to become pregnant during the study.
  2. Patients who in the investigator's judgment, poses a significant drop out risk or life expectancy inferior to study ending.
  3. Patients with anticipated need to change the ART before study ending.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

208 participants in 1 patient group

study group
Experimental group
Description:
HIV-1 infected adults, ART-naive subjects, who start BIC/FTC/TAF using test and treat strategy recruited at infectious diseases units from various Spanish public healthcare centers.
Treatment:
Drug: BIC/FTC/TAF

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems